CN103599167B - A kind of medicament for the treatment of pulmonary carcinoma - Google Patents
A kind of medicament for the treatment of pulmonary carcinoma Download PDFInfo
- Publication number
- CN103599167B CN103599167B CN201310544426.9A CN201310544426A CN103599167B CN 103599167 B CN103599167 B CN 103599167B CN 201310544426 A CN201310544426 A CN 201310544426A CN 103599167 B CN103599167 B CN 103599167B
- Authority
- CN
- China
- Prior art keywords
- pulmonary carcinoma
- medicament
- treatment
- present
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of medicament for the treatment of pulmonary carcinoma, it is made up of following bulk drugs: youth-and-old-age, Herba Vernoniae Cinereae, mangrove bark, the Herba Blumeae Laciniatae, Rhizoma Belamcandae, Fructus Hippophae, Fructus Dracontomeli Duperreani, Semen Canavaliae, Herba Lysimachiae Insignis, mountain Lens culinaris Medic., Chimonanthusn itens Oliv., Coriolous Dersicolor (Fr.) Quel.Medicament of the present invention is with pure traditional Chinese medicine, and keep little, the eutherapeutic characteristic of natural drug toxicity, clear curative effect, can treat pulmonary carcinoma effectively.
Description
Technical field
The present invention relates to tumor radiotherapy field, specifically, relate to a kind of medicament for the treatment of pulmonary carcinoma.
Background technology
Pulmonary carcinoma be body under various carcinogenic factor effect, some cells of local organization lose the normal regulation to its growth on gene level, cause its clonal abnormality hypertrophy and the neoplasm that formed.It is generally acknowledged, lung carcinoma cell is monoclonicity, and all oncocytes namely in a pulmonary carcinoma are all offsprings of the cell of a sudden change.Generally pulmonary carcinoma is divided into optimum and pernicious two large classes.All pernicious pulmonary carcinoma is generically and collectively referred to as cancer.
The chemicals that adopts is treated more clinically at present, but the injury of chemotherapeutics often for patient is larger.
Summary of the invention
The object of this invention is to provide a kind of medicament for the treatment of pulmonary carcinoma.
In order to realize object of the present invention, the invention provides a kind of medicament for the treatment of pulmonary carcinoma, it is made up by weight of following bulk drugs:
Preferably, it is made up by weight of following bulk drugs:
Preferably, medicament of the present invention is tablet, dispersible tablet, decoction or capsule.
Medicament of the present invention is with pure traditional Chinese medicine, and keep little, the eutherapeutic characteristic of natural drug toxicity, clear curative effect, can treat pulmonary carcinoma effectively.
Accompanying drawing explanation
With reference to " Chinese medicine voluminous dictionary " second edition, being described as follows of the crude drug used in the present invention:
Fig. 1 is the explanation of youth-and-old-age;
Fig. 2 is the explanation of Herba Vernoniae Cinereae;
Fig. 3 is the explanation of mangrove bark;
Fig. 4 is the explanation of the Herba Blumeae Laciniatae;
Fig. 5 is the explanation of Rhizoma Belamcandae;
Fig. 6 is the explanation of Fructus Hippophae;
Fig. 7 is the explanation of Fructus Dracontomeli Duperreani;
Fig. 8 is the explanation of Semen Canavaliae;
Fig. 9 is the explanation of Herba Lysimachiae Insignis;
Figure 10 is the explanation of mountain Lens culinaris Medic.;
Figure 11 is the explanation of Chimonanthusn itens Oliv.;
Figure 12 is the explanation of Coriolous Dersicolor (Fr.) Quel.
Detailed description of the invention
Below by way of the description of detailed description of the invention, the invention will be further described, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, various amendment or improvement can be made, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
The preparation of embodiment 1 decoction of the present invention
Get youth-and-old-age 100 grams, Herba Vernoniae Cinereae 100 grams, mangrove bark 30 grams, the Herba Blumeae Laciniatae 30 grams, Rhizoma Belamcandae 100 grams, Fructus Hippophae 50 grams, Fructus Dracontomeli Duperreani 50 grams, Semen Canavaliae 100 grams, Herba Lysimachiae Insignis 50 grams, mountain Lens culinaris Medic. 50 grams, Chimonanthusn itens Oliv. 100 grams, Coriolous Dersicolor (Fr.) Quel 100 grams, be placed in 15000 ml waters, reflux 3 hours at 90 DEG C, filter, obtain filtering residue and filtrate, filtrate is described decoction.
Experimental example
Investigate now the therapeutic effect of medicament of the present invention for pulmonary carcinoma, this is intended to be schematic and nonrestrictive.
Physical data
40 routine patients with lung cancer, are all diagnosed as medium and advanced lung cancer through CT and cytology or pathology.Wherein, man 20 example, female 20 example, minimum 44 years old of age, maximum 76 years old, average 60 years old; Classification: scale cancer 19 example, adenocarcinoma 12 example, mixed carcinoma 9 example.The quality of life Ka Shi equal >30 that marks divides.
Take the decoction of preparation in embodiment 1, one day twice, each 50 milliliters.It within 60 days, is 1 course for the treatment of.Period in a medicine does not all adopt the measures such as any chemotherapy, radiotherapy.
The standard of curative effect evaluation
According to Short-term, appraisal of life quality 2 indexs, observe therapeutic effect.
1. Short-term criterion of therapeutical effect: according to the objective efficacy assessment standard of WHO treatment of cancer (Chinese Anti-Cancer Association. newly organized common pernicious pulmonary carcinoma diagnosis and treatment specification primary bronchogenic carcinoma of lung fascicle [S]. Beijing: combined publication society of China Concord Medical Science University of Beijing Medical University .1999:14-26.541.), different by treatment pulmonary carcinoma size variation, curative effect is divided into 4 grades.1. complete incidence graph: pulmonary carcinoma focus disappears completely and at least maintains more than 4 weeks; 2. partial rcsponse: the maximum gauge of pulmonary carcinoma focus and the product of maximum perpendicular transverse diameter reduce >=and 50%, and maintain more than 4 weeks, occur without new focus; 3. stablize: two footpath products of swollen lame focus reduce <50%, increase <25%, maintain more than 4 weeks, occur without new focus; 4. progress is worsened: pulmonary carcinoma increases >=25% or occur new focus.
2. appraisal of life quality: by Ka Shi standards of grading (look into people person of outstanding talent. modern pulmonary cancer diagnosis and treatment (M) .2 version. Beijing: People's Medical Officer Press .1999:416), after treatment, rising 10 is divided into effectively, it is invalid that decline 10 is divided into, and it is stable for being elevated between 10 points.
Therapeutic outcome
1. Short-term: complete incidence graph 10 example, partial rcsponse 6 example, stablizes 24 examples, worsens progress 0 example.
2. quality of life treats rear Ka Shi scoring, and effective 16 examples of therapeutic effect, therapeutic effect stablizes 24 examples, and therapeutic effect decline 0 is routine.
Untoward reaction and toxic and side effects supervision
By detect patient blood pressure, pulse, whether there is Nausea and vomiting, dizzy clinical symptoms judges untoward reaction.Find that the systolic pressure of 40 routine patients is between 90-140mmHg, diastolic pressure is between 60-90mmHg, and pulse is 60-100 beat/min, and blood pressure and pulse all within normal range, and does not occur Nausea and vomiting, dizzy clinical symptoms.This illustrates that pharmaceutical composition of the present invention does not have obvious untoward reaction, and then proves that this medicine does not have obvious toxic and side effects for human body.
Claims (1)
1. treat a medicament for pulmonary carcinoma, it is characterized in that, it is made up by weight of following bulk drugs:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310544426.9A CN103599167B (en) | 2013-11-07 | 2013-11-07 | A kind of medicament for the treatment of pulmonary carcinoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310544426.9A CN103599167B (en) | 2013-11-07 | 2013-11-07 | A kind of medicament for the treatment of pulmonary carcinoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103599167A CN103599167A (en) | 2014-02-26 |
| CN103599167B true CN103599167B (en) | 2015-11-25 |
Family
ID=50117473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310544426.9A Expired - Fee Related CN103599167B (en) | 2013-11-07 | 2013-11-07 | A kind of medicament for the treatment of pulmonary carcinoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103599167B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104189130B (en) * | 2014-09-26 | 2016-08-24 | 杨嵘 | A kind of pharmaceutical composition treating rhinitis and preparation method and application |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634121A (en) * | 2004-10-15 | 2005-07-06 | 北京正大绿洲医药科技有限公司 | Dripping pills of ganoderma lucidum polysaccharide and polystictus versicolor polysaccharide |
-
2013
- 2013-11-07 CN CN201310544426.9A patent/CN103599167B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634121A (en) * | 2004-10-15 | 2005-07-06 | 北京正大绿洲医药科技有限公司 | Dripping pills of ganoderma lucidum polysaccharide and polystictus versicolor polysaccharide |
Non-Patent Citations (2)
| Title |
|---|
| 云芝糖肽对肺癌病人的前瞻性辅助治疗观察;柯玲，姚培炎，高正明，范思陶;《上海师范大学学报(自然科学版)》;19950331;第24卷(第01期);第66-71页 * |
| 扶正散结片抗肿瘤作用研究;罗斌，韦焕英，韦文俊;《广西中医药》;19951220;第18卷(第06期);第44-46页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103599167A (en) | 2014-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103446525B (en) | Treat dermopathic Chinese medicine composition and its preparation method and application | |
| CN105232623A (en) | Application of cyclocarya paliurus extract in preparation of medicine for treating stomach cancer | |
| CN104857018B (en) | Raspberry polysaccharide prepares the purposes of antineoplastic combination medication with chemotherapeutics | |
| CN112704223A (en) | Composition with auxiliary gastric mucosa protection effect, application thereof and health food | |
| CN103599167B (en) | A kind of medicament for the treatment of pulmonary carcinoma | |
| CN102579514A (en) | Method for processing alangium platanifolium | |
| CN101721403A (en) | Application of fucoxanthin in aspect of losing weight | |
| CN102309708B (en) | Drug for treating tumor | |
| CN102302719B (en) | Medicament for treating tumor | |
| CN101559114A (en) | Application of traditional Chinese medicine composition in preparing antihypoxic | |
| CN105194352B (en) | A kind of Chinese medicine composition and preparation method thereof improving learning and memory | |
| CN104491041B (en) | Gegen Qinlian oral fluid and preparation method thereof | |
| CN103585206A (en) | Preparation method of Chrysosplenium extract and its application | |
| CN104758462B (en) | A kind of powder for the treatment of acute cholecystitis | |
| CN103251882A (en) | Pharmaceutical composition for treating tumor | |
| CN106309585B (en) | A kind of Chinese medicine composition improving tumor patient ostalgia and its application in analgesia | |
| CN104491508A (en) | Pharmaceutical composition for treating herpes zoster | |
| CN106727627A (en) | A kind of medicine for the treatment of cancer and its preparation method and application | |
| CN104857011B (en) | Raspberry polysaccharide prevents or the application for the treatment of toxic and side | |
| CN104758329B (en) | It is a kind of to be used to prevent Chinese medicine composition of chicken coccidiasis and preparation method thereof | |
| CN104069062A (en) | Hilicidum injection for preventing and treating ischemic cardiovascular and cerebrovascular diseases as well as preparation method and application thereof | |
| Yamamoto et al. | Disopyramide-induced pneumonitis, diagnosed by lymphocyte stimulation test using bronchoalveolar lavage fluid | |
| CN104069119B (en) | A kind of application of helicidum and preparation | |
| CN108210760A (en) | A kind of preparation method for the drug for treating lung cancer | |
| CN103169884B (en) | Blood glucose reducing composition, medicine or health-care product containing blood glucose reducing composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151125 Termination date: 20161107 |